INNATE PHARMA SA (IPH.PA) Fundamental Analysis & Valuation

EPA:IPH • FR0010331421

Current stock price

1.2 EUR
+0.01 (+0.5%)
Last:

This IPH.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. IPH.PA Profitability Analysis

1.1 Basic Checks

  • IPH had negative earnings in the past year.
  • In the past year IPH has reported a negative cash flow from operations.
  • In the past 5 years IPH always reported negative net income.
  • IPH had a negative operating cash flow in each of the past 5 years.
IPH.PA Yearly Net Income VS EBIT VS OCF VS FCFIPH.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -78.41%, IPH is doing worse than 79.17% of the companies in the same industry.
Industry RankSector Rank
ROA -78.41%
ROE N/A
ROIC N/A
ROA(3y)-42.35%
ROA(5y)-34.95%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IPH.PA Yearly ROA, ROE, ROICIPH.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 -400

1.3 Margins

  • Looking at the Gross Margin, with a value of 1.29%, IPH is doing worse than 63.89% of the companies in the same industry.
  • IPH's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for IPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 1.29%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-75.94%
GM growth 5Y-57.54%
IPH.PA Yearly Profit, Operating, Gross MarginsIPH.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. IPH.PA Health Analysis

2.1 Basic Checks

  • IPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, IPH has more shares outstanding
  • The number of shares outstanding for IPH has been increased compared to 5 years ago.
  • IPH has a worse debt/assets ratio than last year.
IPH.PA Yearly Shares OutstandingIPH.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
IPH.PA Yearly Total Debt VS Total AssetsIPH.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • IPH has an Altman-Z score of -11.35. This is a bad value and indicates that IPH is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of IPH (-11.35) is worse than 79.17% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.35
ROIC/WACCN/A
WACC7.2%
IPH.PA Yearly LT Debt VS Equity VS FCFIPH.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 1.27 indicates that IPH should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.27, IPH is doing worse than 66.67% of the companies in the same industry.
  • A Quick Ratio of 1.27 indicates that IPH should not have too much problems paying its short term obligations.
  • IPH's Quick ratio of 1.27 is on the low side compared to the rest of the industry. IPH is outperformed by 63.89% of its industry peers.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.27
IPH.PA Yearly Current Assets VS Current LiabilitesIPH.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. IPH.PA Growth Analysis

3.1 Past

  • IPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.35%, which is quite good.
  • Looking at the last year, IPH shows a very negative growth in Revenue. The Revenue has decreased by -77.92% in the last year.
  • IPH shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -45.15% yearly.
EPS 1Y (TTM)10.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0.82%
Revenue 1Y (TTM)-77.92%
Revenue growth 3Y-61.69%
Revenue growth 5Y-45.15%
Sales Q2Q%-74.22%

3.2 Future

  • The Earnings Per Share is expected to decrease by -12.83% on average over the next years. This is quite bad
  • Based on estimates for the next years, IPH will show a very strong growth in Revenue. The Revenue will grow by 46.26% on average per year.
EPS Next Y13.33%
EPS Next 2Y-32.12%
EPS Next 3Y-12.83%
EPS Next 5YN/A
Revenue Next Year-2.22%
Revenue Next 2Y-22.02%
Revenue Next 3Y30.65%
Revenue Next 5Y46.26%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IPH.PA Yearly Revenue VS EstimatesIPH.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
IPH.PA Yearly EPS VS EstimatesIPH.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.2 -0.4 -0.6 -0.8

More info and screens

Find the best growth stocksShow best growing peers

0

4. IPH.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IPH. In the last year negative earnings were reported.
  • Also next year IPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IPH.PA Price Earnings VS Forward Price EarningsIPH.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPH.PA Per share dataIPH.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4 -0.5

4.3 Compensation for Growth

  • IPH's earnings are expected to decrease with -12.83% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-32.12%
EPS Next 3Y-12.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IPH.PA Dividend Analysis

5.1 Amount

  • No dividends for IPH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IPH.PA Fundamentals: All Metrics, Ratios and Statistics

INNATE PHARMA SA

EPA:IPH (4/30/2026, 7:00:00 PM)

1.2

+0.01 (+0.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength36.49
Industry Growth78
Earnings (Last)04-01
Earnings (Next)N/A
Inst Owners8.34%
Inst Owner ChangeN/A
Ins Owners1.22%
Ins Owner ChangeN/A
Market Cap112.60M
Revenue(TTM)2.79M
Net Income(TTM)-49.18M
Analysts82.5
Price Target6.27 (422.5%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)3.7%
EPS NY rev (3m)3.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-0.29%
Revenue NY rev (3m)-28.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 40.4
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.56
OCFYN/A
SpS0.03
BVpS-0.23
TBVpS-0.23
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -78.41%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 1.29%
FCFM N/A
ROA(3y)-42.35%
ROA(5y)-34.95%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-75.94%
GM growth 5Y-57.54%
F-Score0
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.12%
Cap/Sales 5.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.27
Quick Ratio 1.27
Altman-Z -11.35
F-Score0
WACC7.2%
ROIC/WACCN/A
Cap/Depr(3y)25.32%
Cap/Depr(5y)21.48%
Cap/Sales(3y)4.22%
Cap/Sales(5y)5.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0.82%
EPS Next Y13.33%
EPS Next 2Y-32.12%
EPS Next 3Y-12.83%
EPS Next 5YN/A
Revenue 1Y (TTM)-77.92%
Revenue growth 3Y-61.69%
Revenue growth 5Y-45.15%
Sales Q2Q%-74.22%
Revenue Next Year-2.22%
Revenue Next 2Y-22.02%
Revenue Next 3Y30.65%
Revenue Next 5Y46.26%
EBIT growth 1Y0.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year767.26%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-625.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-665.01%
OCF growth 3YN/A
OCF growth 5YN/A

INNATE PHARMA SA / IPH.PA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for INNATE PHARMA SA?

ChartMill assigns a fundamental rating of 1 / 10 to IPH.PA.


What is the valuation status for IPH stock?

ChartMill assigns a valuation rating of 0 / 10 to INNATE PHARMA SA (IPH.PA). This can be considered as Overvalued.


What is the profitability of IPH stock?

INNATE PHARMA SA (IPH.PA) has a profitability rating of 0 / 10.


Can you provide the financial health for IPH stock?

The financial health rating of INNATE PHARMA SA (IPH.PA) is 1 / 10.